血清抵抗素与多细胞因子炎症通路与2型糖尿病全因死亡的关联及预测价值
本研究在3个队列共1528例2型糖尿病患者(409例死亡)及59例颈动脉内膜剥脱术患者中,评估血清抵抗素与多细胞因子炎症通路(REMAP)与全因死亡的关系。
要点
- REMAP评分与2型糖尿病患者全因死亡独立相关,每增加1个标准差HR=1.34。
- REMAP可改善Estimation of Mortality Risk in Type 2 Diabetic Patients和Risk Equations for Complications of Type 2 Diabetes模型的预测性能。
核心结论
- REMAP与2型糖尿病全因死亡独立相关,并提高对全因死亡的预测能力,可用于识别需更积极管理的高危个体。
研究设计与样本
- 研究在3个队列共1528例2型糖尿病患者(409例死亡)及59例接受颈动脉内膜剥脱术患者中评估REMAP评分。
- 斑块按改良美国心脏协会动脉粥样硬化分类标准分为不稳定/稳定。
临床怎么用
- REMAP评分可用于2型糖尿病患者的风险分层,辅助识别全因死亡高风险个体以实施更积极的管理。
局限性
- REMAP能否识别对IL-6和IL-1β单克隆抗体治疗更敏感的患者,尚需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Type 2 diabetes (T2D) shows a high mortality rate, partly mediated by atherosclerotic plaque instability. Discovering novel biomarkers may help identify high-risk patients who would benefit from more aggressive and specific managements. We recently described a serum resistin and multicytokine inflammatory pathway (REMAP), including resistin, interleukin (IL)-1β, IL-6, IL-8, and TNF-α, that is associated with cardiovascular disease. OBJECTIVE: We investigated whether REMAP is associated with and improves the prediction of mortality in T2D. METHODS: A REMAP score was investigated in 3 cohorts comprising 1528 patients with T2D (409 incident deaths) and in 59 patients who underwent carotid endarterectomy (CEA; 24 deaths). Plaques were classified as unstable/stable according to the modified American Heart Association atherosclerosis classification. RESULTS: REMAP was associated with all-cause mortality in each cohort and in all 1528 individuals (fully adjusted hazard ratio [HR] for 1 SD increase = 1.34, P < .001). In CEA patients, REMAP was associated with mortality (HR = 1.64, P = .04) and a modest change was observed when plaque stability was taken into account (HR = 1.58; P = .07). REMAP improved discrimination and reclassification measures of both Estimation of Mortality Risk in Type 2 Diabetic Patients and Risk Equations for Complications of Type 2 Diabetes, well-established prediction models of mortality in T2D (P < .05-< .001). CONCLUSION: REMAP is independently associated with and improves predict all-cause mortality in T2D; it can therefore be used to identify high-risk individuals to be targeted with more aggressive management. Whether REMAP can also identify patients who are more responsive to IL-6 and IL-1β monoclonal antibodies that reduce cardiovascular burden and total mortality is an intriguing possibility to be tested.
引用
- Scarale MG, Antonucci A, Cardellini M, et al. A Serum Resistin and Multicytokine Inflammatory Pathway Is Linked With and Helps Predict All-cause Death in Diabetes. J Clin Endocrinol Metab. 2021. PMID: 34192323. doi:10.1210/clinem/dgab472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。